CapsoVision, Inc. logo

CapsoVision, Inc. (CV)

Market Closed
11 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
6. 89
-0.35
-4.8343%
Pre Market
$
7. 50
+0.61 +8.8534%
350.74M Market Cap
- P/E Ratio
- Div Yield
84,643 Volume
- Eps
$ 7.24
Previous Close
Investors:
Add Transaction
Day Range
6.83 7.27
Year Range
3.43 15.37
Want to track CV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CV closed today lower at $6.89, a decrease of -4.8343% from yesterday's close, completing a monthly decrease of -2.546% or -$0.18. Over the past 12 months, CV stock lost -36.4977%.
CV is not paying dividends to its shareholders.
The last earnings report, released on Jun 03, 2026, exceeded the consensus estimates by 0.12%. On average, the company has surpassed earnings expectations by 0.1433%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

CV Chart

People also search for

Celldex Therapeutics Inc.
$ 29.96
+2.0784%
Immunome Inc.
$ 18.36
+1.1013%
Astrana Health Inc.
$ 39.85
+2.8918%
UFP Technologies Inc.
$ 238.6
+2.6325%
Viridian Therapeutics Inc.
$ 16.14
+2.3462%
CapsoVision Q1 Earnings Call Highlights

CapsoVision Q1 Earnings Call Highlights

CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.

Marketbeat | 4 weeks ago
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript

CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript

CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript

Seekingalpha | 4 weeks ago
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript

CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript

CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript

Seekingalpha | 2 months ago

CapsoVision, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
JC
Joseph Castro Nuveen LLC
33,098 $241,284 $228,045.22 -$13,238.78 -5.49%
Alexandra Stickelman
Alexandra Stickelman Root Financial Partners, LLC
38 $277 $261.82 -$15.18 -5.48%
MS
Mark Schafer Police & Firemen's Retirement System of New Jersey
6,958 $50,724 $47,940.62 -$2,783.38 -5.49%

CapsoVision, Inc. (CV) FAQ

What is the stock price today?

The current price is $6.89.

On which exchange is it traded?

CapsoVision, Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is CV.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 350.74M.

Has CapsoVision, Inc. ever had a stock split?

No, there has never been a stock split.

CapsoVision, Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Kang-Huai Wang CEO
NASDAQ (CM) Exchange
140935107 CUSIP
US Country
90 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

The company is a leader in the medical technology sector, specializing in the development of innovative solutions for gastrointestinal diagnostics. Their commitment to advancing healthcare is evident through their cutting-edge products, such as the CapsoCam Plus and CapsoCam Colon systems, which utilize capsule endoscopy. These technologies enhance the precision and effectiveness of gastrointestinal examinations and empower healthcare professionals with more reliable data. Additionally, the integration of artificial intelligence in their imaging platforms signifies a forward-thinking approach, aiming to improve the diagnostic process and overall patient care. By leveraging advanced technology and continuous research, the company strives to redefine standards in the medical diagnostics industry.

Products and Services

  • CapsoCam Plus:

    This advanced capsule endoscopy system offers a comprehensive solution for visualizing the small intestine. With its 360-degree imaging capabilities, the CapsoCam Plus allows for detailed examination and facilitates early detection of gastrointestinal diseases.

  • CapsoCam Colon:

    Designed specifically for colon examination, CapsoCam Colon combines ease of use with high-resolution imaging. This system helps clinicians to achieve thorough assessments of the colon, enhancing the overall diagnostic accuracy for conditions such as polyps and colorectal cancer.

  • AI-Enabled Imaging Platforms:

    These platforms are equipped with artificial intelligence capabilities that assist in the interpretation of images captured during endoscopic procedures. The AI technology enhances diagnostic precision, aids in identifying abnormalities, and supports clinicians in making informed decisions regarding patient care.

Contact Information

Address: Cox Avenue
Phone: 14086241488